JP7090551B2 - 眼状態の治療方法 - Google Patents

眼状態の治療方法 Download PDF

Info

Publication number
JP7090551B2
JP7090551B2 JP2018553080A JP2018553080A JP7090551B2 JP 7090551 B2 JP7090551 B2 JP 7090551B2 JP 2018553080 A JP2018553080 A JP 2018553080A JP 2018553080 A JP2018553080 A JP 2018553080A JP 7090551 B2 JP7090551 B2 JP 7090551B2
Authority
JP
Japan
Prior art keywords
formula
compound
iiia
iiib
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513759A (ja
JP2019513759A5 (https=
Inventor
ダグラス マイケル ジュニア アッカーマン
ジェームズ ルーディン
ケネス ジェイ． マンデル
Original Assignee
オイスター ポイント ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オイスター ポイント ファーマ インコーポレイテッド filed Critical オイスター ポイント ファーマ インコーポレイテッド
Publication of JP2019513759A publication Critical patent/JP2019513759A/ja
Publication of JP2019513759A5 publication Critical patent/JP2019513759A5/ja
Priority to JP2022095460A priority Critical patent/JP2022120125A/ja
Application granted granted Critical
Publication of JP7090551B2 publication Critical patent/JP7090551B2/ja
Priority to JP2024086805A priority patent/JP2024103594A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2018553080A 2016-04-07 2017-04-06 眼状態の治療方法 Active JP7090551B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022095460A JP2022120125A (ja) 2016-04-07 2022-06-14 眼状態の治療方法
JP2024086805A JP2024103594A (ja) 2016-04-07 2024-05-29 眼状態の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
US62/319,648 2016-04-07
PCT/US2017/026385 WO2017177024A1 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022095460A Division JP2022120125A (ja) 2016-04-07 2022-06-14 眼状態の治療方法

Publications (3)

Publication Number Publication Date
JP2019513759A JP2019513759A (ja) 2019-05-30
JP2019513759A5 JP2019513759A5 (https=) 2020-05-14
JP7090551B2 true JP7090551B2 (ja) 2022-06-24

Family

ID=58549326

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553080A Active JP7090551B2 (ja) 2016-04-07 2017-04-06 眼状態の治療方法
JP2022095460A Pending JP2022120125A (ja) 2016-04-07 2022-06-14 眼状態の治療方法
JP2024086805A Pending JP2024103594A (ja) 2016-04-07 2024-05-29 眼状態の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022095460A Pending JP2022120125A (ja) 2016-04-07 2022-06-14 眼状態の治療方法
JP2024086805A Pending JP2024103594A (ja) 2016-04-07 2024-05-29 眼状態の治療方法

Country Status (19)

Country Link
US (3) US10709707B2 (https=)
EP (2) EP3439661B1 (https=)
JP (3) JP7090551B2 (https=)
KR (2) KR102485299B1 (https=)
CN (3) CN109310692B (https=)
AU (1) AU2017248276B2 (https=)
DK (1) DK3439661T3 (https=)
EA (1) EA201892265A1 (https=)
ES (1) ES2893126T3 (https=)
IL (3) IL299204A (https=)
MX (2) MX385698B (https=)
MY (1) MY199237A (https=)
NZ (1) NZ746468A (https=)
PH (1) PH12018502154A1 (https=)
PT (1) PT3439661T (https=)
SG (1) SG11201808650QA (https=)
TW (2) TWI790997B (https=)
WO (1) WO2017177024A1 (https=)
ZA (1) ZA201807438B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
CN109310692B (zh) 2016-04-07 2022-01-25 奥伊斯特普安生物制药公司 治疗眼部病状的方法
TW202019417A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
ES3039903T3 (en) 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN117355307A (zh) * 2021-05-07 2024-01-05 奥伊斯特普安生物制药公司 载体与烟碱激动剂的协同疗法
WO2026080563A1 (en) 2024-10-09 2026-04-16 Oyster Point Pharma, Inc. Simpinicline oral formations and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531168A (ja) 2000-04-21 2003-10-21 インスパイアー ファーマシューティカルズ，インコーポレイティド ニコチン・アセチルコリン受容体アゴニストによるドライ・アイ疾患の治療方法
JP2012510471A (ja) 2008-12-01 2012-05-10 ターガセプト，インコーポレイテッド （ｒ）−５−（（ｅ）−２−（ピロリジン−３−イルビニル）ピリミジンの合成および新規の塩形態
JP2017531044A (ja) 2014-10-20 2017-10-19 オイスター ポイント ファーマ インコーポレイテッド 眼の病状の治療方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
EP1461040B1 (en) 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
MX2007004495A (es) 2004-10-15 2007-05-10 Pfizer Prod Inc Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
WO2006100075A2 (en) 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
AU2008211613B2 (en) 2007-02-02 2013-05-23 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2010028033A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
JP2012505834A (ja) * 2008-10-14 2012-03-08 サイコジェニックス・インコーポレーテッド ニコチン性アセチルコリン受容体リガンドおよびその使用
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) * 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CN102802630A (zh) * 2009-06-17 2012-11-28 塔加西普特公司 通过神经元烟碱受体配体逆转左旋多巴诱导的运动障碍
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
JP6162705B2 (ja) 2011-10-20 2017-07-12 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー
CN104094114A (zh) 2011-11-30 2014-10-08 黛尔格诺斯蒂尔有限公司 干眼诊断
CN109310692B (zh) 2016-04-07 2022-01-25 奥伊斯特普安生物制药公司 治疗眼部病状的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531168A (ja) 2000-04-21 2003-10-21 インスパイアー ファーマシューティカルズ，インコーポレイティド ニコチン・アセチルコリン受容体アゴニストによるドライ・アイ疾患の治療方法
JP2012510471A (ja) 2008-12-01 2012-05-10 ターガセプト，インコーポレイテッド （ｒ）−５−（（ｅ）−２−（ピロリジン−３−イルビニル）ピリミジンの合成および新規の塩形態
JP2017531044A (ja) 2014-10-20 2017-10-19 オイスター ポイント ファーマ インコーポレイテッド 眼の病状の治療方法

Also Published As

Publication number Publication date
US10709707B2 (en) 2020-07-14
IL262102B (en) 2022-03-01
ES2893126T8 (es) 2022-05-23
TW201737917A (zh) 2017-11-01
CN114533737A (zh) 2022-05-27
TW202320785A (zh) 2023-06-01
TWI790997B (zh) 2023-02-01
BR112018070497A2 (pt) 2019-01-29
CA3020170A1 (en) 2017-10-12
US20200345734A1 (en) 2020-11-05
CN114432313A (zh) 2022-05-06
EP3439661B1 (en) 2021-08-04
PH12018502154A1 (en) 2019-07-08
AU2017248276A1 (en) 2018-11-22
CN109310692B (zh) 2022-01-25
WO2017177024A1 (en) 2017-10-12
JP2019513759A (ja) 2019-05-30
DK3439661T3 (da) 2021-10-18
EP3970724A1 (en) 2022-03-23
SG11201808650QA (en) 2018-10-30
PT3439661T (pt) 2021-09-30
ZA201807438B (en) 2024-09-25
ES2893126T3 (es) 2022-02-08
IL262102A (en) 2018-11-29
EA201892265A1 (ru) 2019-04-30
IL290069A (en) 2022-03-01
MY199237A (en) 2023-10-22
KR20190005859A (ko) 2019-01-16
CN114533737B (zh) 2024-05-31
US20250000861A1 (en) 2025-01-02
MX385698B (es) 2025-03-18
EP3439661A1 (en) 2019-02-13
KR20230010813A (ko) 2023-01-19
IL290069B2 (en) 2023-05-01
NZ785093A (en) 2024-07-05
JP2024103594A (ja) 2024-08-01
WO2017177024A8 (en) 2018-11-08
KR102512777B1 (ko) 2023-03-23
CN109310692A (zh) 2019-02-05
NZ746468A (en) 2023-06-30
KR102485299B1 (ko) 2023-01-06
IL290069B1 (en) 2023-01-01
IL299204A (en) 2023-02-01
AU2017248276B2 (en) 2023-07-13
TWI876258B (zh) 2025-03-11
MX2021010399A (es) 2022-01-18
US20190201397A1 (en) 2019-07-04
JP2022120125A (ja) 2022-08-17
MX2018012230A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
JP7090551B2 (ja) 眼状態の治療方法
US11224598B2 (en) Methods of increasing lacrimal proteins
HK40063370A (en) Methods of treating ocular conditions
EA047371B1 (ru) Применение соединения при лечении сухости глаз или дискомфорта в глазах
EA040442B1 (ru) Применение соединения при лечении сухости глаз или дискомфорта в глазах
HK40004067B (en) Methods of treating ocular conditions
BR112018070497B1 (pt) Métodos e formulações farmacêuticas para tratamento de condições oculares
CA3020170C (en) Methods of treating ocular conditions
HK40035962A (en) Methods of treating ocular conditions
HK40035961A (en) Methods of treating ocular conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210415

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220614

R150 Certificate of patent or registration of utility model

Ref document number: 7090551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250